TNFRSF17 and plasma cell myeloma: Compared to the MGUS, MM patients were characterized by an evident rise in MYEOV+ myeloma cells, in which a clear upregulation of TNFSF13B receptors, TNFRSF13B and TNFRSF17, was detected (Figures 1C, D).